Pembrolizumab was the first anti-PD-1 antibody to be approved by the US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma with disease progression following ipilimumab, and if BRAFV600 mutation positive, a BRAF inhibitor. This evidence concerns the gene BRAF and metastatic melanoma.